ClinicalTrials.gg
Status unknownNCT04370470LSAUpdated May 1, 2020

Development of Assessments for Later Stage HD

An observational study in Huntington Disease, sponsored by CHDI Foundation, Inc.. Status unknown at 20 sites in 2 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-05-01.

Sponsored by CHDI Foundation, Inc. · Observational

How we know

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
340
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Huntington Disease by CHDI Foundation, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Huntington Disease · CHDI Foundation, Inc..

Started
2020
with 2 others
Observational
7 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Huntington Disease by CHDI Foundation, Inc., this one is one of 3 that started in 2020, is one of 7 observational ones, and was the 9th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

2 of the 11 studies in Huntington Disease by CHDI Foundation, Inc. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Huntington Disease by CHDI Foundation, Inc., or all of them as a file.
02

Study summary

Later Stage HD Assessments (LSA) is an observational, multinational study aiming at developing two assessments that can be used to measure critical milestones and events during the later stages of Huntington's disease (HD). An important aspect of the evaluation will be to assess whether the assessments can be administered to a companion either in-person or remotely (i.e. by phone contact with the companion). Therefore, these assessments will be evaluated for their internal consistency, reliability and validity. Once established, these assessments may be incorporated into a large scale, global observational study of HD and/or other HD clinical studies as well as use them for planning clinical trials.

Read the detailed description

The primary objective of this study is to evaluate the internal consistency, reliability and validity of two assessments: (1) UHDRS Structured Interview of Function (SIF) that incorporates the UHDRS Total Functional Capacity, Functional Assessment Scale, and Independence Scale (UHDRS TFC, FAS and IS), and (2) the HD Clinical Status Questionnaire (HDCSQ). There will be two study parts: Part 1 will measure the performance of the UHDRS SIF assessment compared to the original UHDRS TFC, FAS and IS using a cross-over design by collecting data from the Manifest HD gene expansion carrier participants (Manifest HDGEC Participants) and their companions (Companion Participants) via an in-person baseline visit and a follow-up visit by phone. Part 2 will assess the UHDRS SIF and the HDCSQ using a cross-sectional design by collecting data from the Companion Participants via a follow-up visit by phone. Participants of Part 1 are eligible to participate in Part 2.

03

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • CHDI
  • Huntington Disease
  • Huntington's Disease
  • Huntington's Disease Later Stage
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Manifest HDGEC Participants: Manifest HDGEC Participants must be participants in the Enroll-HD study. Manifest HDGEC Participants will be recruited from English-speaking study sites participating in the Enroll-HD study.

Companion Participants: Companions Participants will be identified for Manifest HDGEC Participants and asked to participate. A Companion Participant's participation for a Manifest HDGEC participant is mandatory.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following inclusion criteria to participate in this study:

All Participants

  1. Individual of either gender
  2. Fluent in English
  3. Must be willing and able to provide or have a legal representative willing and able to provide assent

Manifest HDGEC Participants

  1. Must be an active participant in the Enroll-HD study. An active participant is defined as a participant who has successfully enrolled in the Enroll-HD study and completed the Enroll-HD study baseline visit.
  2. Age≥20 years
  3. CAG repeat length≥36
  4. DCL=4
  5. Inclusion score of 16 at the time of the participant's most recent Enroll-HD study visit (for inclusion score calculation, see Appendix A - Inclusion Score Calculation) Companion Participants
  1. Age≥18 years 2. A person who, in his/her opinion, has sufficient interface and knowledge of the Manifest HDGEC Participant's capabilities and daily activities 3. Acceptable to the Manifest HDGEC Participant and the Site Investigator or the Site Investigator's designees

Exclusion criteria

Exclusion Criteria:

People who meet the following criteria will be excluded from participating in this study:

  1. Individuals with choreic movement disorders in the context of a laboratory verified non-expansion mutation for the Huntingtin gene
  2. Manifest HDGEC Participants with Juvenile-onset HD (rater estimate of age of onset \<20 years old)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
340 participants (estimated)
Target follow-up
21 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. The UHDRS SIF ratings

    The equivalence of the original UHDRS function scales (TFC, FAS and IS) and the UHDRS SIF will be evaluated using a cross-over design study, with two baseline measurements and one follow up measurement. We will use ICC (Intraclass Correlation Coefficient) and Lin's correlation coefficient will be used to measure the agreement between raters across Participants.

    Time frame: 3 weeks

  2. Clinimetric properties of the UHDRS SIF

    To assess the clinimetric properties of the UHDRS SIF we will use Classical Test Theory (CTT) and Item Response Theory (IRT)

    Time frame: 3 weeks

07

Study locations

20 sites
  • The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    • Jenna Smith · Contactjltidwell@uabmc.edu · 205-996-2807
    • Victor Sung, MD · Principal investigator
  • Regents of the University of California, San Diego
    La Jolla, California 92037, United States
    • Chase Snell · Contactcmsnell@ucsd.edu · 858-249-0569
    • Jody Corey-Bloom, MD · Principal investigator
  • Regents of the University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Rocky Mountain Movement Disorders Center, P.C
    Englewood, Colorado 80113, United States
    • Jessica Jaynes · Contactjaynes@kumarneuro.com · 303-357-5456
    • Rajeev Kumar, MD · Principal investigator
  • Rush Universiity Medical Center
    Chicago, Illinois 60612, United States
  • Hereditary Neurological Disease Centre, Inc.
    Wichita, Kansas 67226, United States
    • Gregory Suter · Contacthndcentre@aol.com · 316-609-3020
    • William Mallonee, MD · Principal investigator
  • Washington University
    Saint Louis, Missouri 63110, United States
    • Stacey K Barton · Contactbartons@wustl.edu · 314-362-3471
    • Joel S Perlmutter · Principal investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • University of Washington
    Seattle, Washington 98195, United States
    • Leigh Beth Latham · Contactbtlatham@uw.edu · 206-685-6602
    • Anny Lin, MD · Principal investigator
  • The Chancellor, Masters and Scholars of the University of Cambridge
    Cambridge, Cambridgeshire CB2 0PY, United Kingdom
    • Priya Rogers · Contactpr466@cam.ac.uk · 01223 331160
    • Roger Barker, MD · Principal investigator
  • Cardiff University
    Wales, Cardiff CF144XN, United Kingdom
  • Royal Devon and Exeter NHS Foundation Trust
    Exeter, Devon EX2 5DW, United Kingdom
    • Sarah Irvine · Contactsarah.irvine@nhs.net · 01392406979
    • Timothy Harrower, MD · Principal investigator
  • Poole Hospital NHS
    Poole, Dorset BH15 2JB, United Kingdom
  • Leicestershire Partnership NHS Trust
    Leicester, Leicestershire LE2 2PL, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, Leicester OX3 9DU, United Kingdom
  • Northumberland, Tyne &Wear NHS Foundation Trust of St. Nicholas Hospital
    Newcastle Upon Tyne, Tyne & Wear NE6 4QD, United Kingdom
  • Birmingham and Solihull Mental Health NHS Foundation
    Birmingham, West Midlands B152FG, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, Yorkshire LS7 4SA, United Kingdom
  • University Hospitals Plymouth NHS Trust
    Plymouth, PL6 8BQ, United Kingdom
    • Jemma Inches · Contactjinches@nhs.net · 0175243845
    • Rupert Noad, MD · Principal investigator
  • Sheffield Children's NHS Foundation Trust
    Sheffield, S5 7AU, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2020; primary completion for Mar 2022, 18 months later.

Of 34 observational studies under Huntington Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
May 1, 2020
StartEst.
Sep 2020
Primary completionEst.
Mar 2022
CompletionEst.
Mar 2022
Last update
May 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04370470
Lead sponsor
CHDI Foundation, Inc.
Responsible party
Sponsor
First posted
May 1, 2020
Start date
Sep 2020 (estimated)
Primary completion
Mar 2022 (estimated)
Completion
Mar 2022 (estimated)
Last update
May 1, 2020

Study contacts

Jamie Levy
Contact
jamie.levey@enroll-hd.org
+1-609-945-9600

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion